As such, when evaluating single-arm trial data for checkpoint inhibitors (including pembrolizumab studies such as KEYNOTE-158), it is likely that any association between tumor PD-L1 CPS and a favorable outcome is representative of predictive value rather than of selection of patients with improved prognosis. This evidence concerns the gene CD274 and neoplasm.